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Abstract
A progress in treatment of hematological cancers was achieved. Unfortunately, 
some youngsters, because of rare genetic alterations that are not easy to detect, as 
well as heavily pretreated old patients, because of coexisting diseases that lead to 
changes in patient metabolism, do not respond to therapy. Moreover, sometimes 
familiar diversities and alterations on genetic or epigenetic level that could be 
transferred on diversities in metabolism or cell signaling might be a reason why 
patients do not respond to therapy. Interestingly, for older patients a resistance to 
therapy could also occur as a reason of drug cross-reactivity. For designing of effec-
tive anticancer therapy for patient with chronic lymphocytic leukemia before drug 
administration, patient’s leukemic cell response to anticancer drug(s) should be 
checked. Moreover, for patient response to treatment, also drugs prescribed previ-
ously by other medical doctors or even patients’ diet could be important for achiev-
ing therapeutic success of therapy. Therefore it is important to choose the effective 
drugs before their administration to patient that will improve treatment efficacy 
and exclude resistance to therapy. It must be stated that the special attention for 
personalized therapy tests should be focused on patients previously resistant to 
therapy, more sensitive to drugs or heavily pretreated.
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1. Introduction
Several studies around the world are focus on molecular aspects related with 
developing of cancer. It seems to be not easy, because of high complexity of 
carcinogenesis and a difference between patients in disease progressing based 
on genetic, epigenetic or even environmental alteration. It is possible that in our 
bodies expression of proteins or external factors regulate hormone expression. 
Moreover, hormones could affect cell signal transduction and metabolism. It looks 
like we have some logical plan that coordinates gene expression, but because of 
potential involvement of many factors and familiar, sometimes even personal, 
predispositions for particular type of disease, diagnostic is not easy. The personal 
differences in disease progression activity and response to treatment reveal that 
even now cancers are the leading cause of death. The best way to avoid carcinogen-
esis is a health prophylactic since childhood. It is more likely that cancer or other 
diseases related with some disturbances in metabolism, except genetically related 
Molecular Medicine
2
documented cases, will develop in the group of overweight people with metabolic 
or hormonal disturbances and without physical exercises. For good health condition 
since childhood, we need to supplement probiotic bacteria to have bacterial flora 
in intestines that could cooperate somehow and save people against most infec-
tions and inflammation [1]. Moreover, it is very important what we consume. Food 
processing should be ecological, without unhealthy chemical additives [2, 3]. It 
must be underlined that health prophylactic might decrease the risk of getting ill or 
even save us from many diseases, including cancers. Proper screening tests that are 
able to find health problems in not advanced phase of disease are very important for 
prophylactic. It is extremely important to discover disease in early stage of develop-
ment so we can effectively help patient to cure the disease, achieving success. It is 
always better and also cheaper to prevent than to cure diseases.
Before we had enough knowledge to cure successive cancers, the most effective 
in the war against cancers seems to be a prophylactic. The prophylactic tests should 
be designed for each person individually based on personal or genetic predisposi-
tions, work-related conditions, weight, or diet. Prophylactic test program should be 
organized by the Ministry of Health and paid from money directed to health service 
from our taxes.
The suitable prophylactic for professions, and increasing knowledge about 
disease development, could enlarge human life and decrease number of cases of 
cardiovascular diseases (e.g. stroke or heart attack). Therefore, we must remember 
that the special diet and physical exercises are able to regulate our hormone level, 
metabolism, and cell signaling leading to homeostasis [4, 5]. The disturbances 
in homeostasis could accompany the development of many diseases, including 
cancers.
There are several different types of lymphoproliferative disorders, characterized 
by disturbances in cell cycle and/or signal transduction that lead to fast prolifera-
tion of cancer cells (acute form) [6]. The other chronic type of neoplasm is caused, 
for example, by abrogation in apoptosis induction leading to accumulation of 
leukemic cells in peripheral blood. It was previously reported that in patient blood 
a quiescent and cycling cells were found that could be a problem in diagnostics and 
treatment [7–9].
Chronic lymphocytic leukemia (CLL), except bone marrow transplantation, 
for some patients is incurable. CLL usually occurs in older individuals but in 
youngsters could transform into a more aggressive form with fast developing 
disease [8].
Interestingly, a high heterogeneity in disease development, the characteristic 
accumulation in patient blood of mainly resting B lymphocytes, was observed. 
Leukemic cells accumulate in patient peripheral blood, because of inhibition in 
induction of apoptosis.
Several factors, even patient diet, could affect disease development and trans-
formation into active form. It could lead to disturbances in cell cycle leading to 
increased cancer cell proliferation index. It could also induce changes in cell sensi-
tivity to drug(s) [10]. The results of experiments directed toward personalization 
of therapy for CLL patients revealed that it is important to analyze before drug(s) 
administration if drug(s) will be active for this patient curing [10–14]. Moreover, 
during leukemic cell incubation with drugs, we are able to check also patients’ 
cell sensitivity to in vitro incubation conditions. If in control untreated cells, cell 
viability decreases similarly like in treated ones, it is an indication that patient 
might need a reduction in drug dose in vivo [15]. Moreover, we need more knowl-
edge on this topic to be able precisely to transform drug doses obtained in patient’s 
blood into in vitro conditions. It must be underlined that for some patients more 
sensitive to drug(s) than others using above tests in vitro we are able to choose the 
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proper drug(s) dose to optimize drug(s) doses administration in vivo. For patients 
responding to treatment in nonstandard way and for patients more sensitive than 
others to drugs, a personalized therapy test could be a chance to choose effective 
treatment for curing to avoid drug resistance, patient fatigue or sometimes also 
secondary cancers. Moreover, the ineffective treatment might reduce patients’ life 
longevity. Therefore it is very important to check before administration if drug 
will be active to patient or in the case of resistance to search for other potentially 
effective drug.
The special value of personalized therapy tests is presented in Figure 1. The 
representative combined results obtained for CLL patient by tests such as cell 
viability (flow cytometry; Vybrant Apoptosis Assay), analyses of thermal profiles 
of nuclei (differential scanning calorimetry) and PARP expression/proteolytic 
cleavage (Western blot) for patient confirm the value for such test in choosing 
effective therapy for CLL patient (Figure 1). The representative results for CLL 
patient confirm that leukemic cells were more sensitive to the combination of 
cladribine and cyclophosphamide/mafosfamide than the combination of fluda-
rabine and cyclophosphamide/mafosfamide. For this patient adding rituximab 
does not change anything in cells’ reactivity to drugs (compare CM and Rit20CM 
results). The combination of cladribine and cyclophosphamide/mafosfamide will 
be more effective for this patient curing than the combination including fludara-
bine. Moreover, the addition of monoclonal antibody to CM combination did not 
change anything when we analyze all results obtained for patient.
In Figure 2 there is an explanation why we should analyze each patient results 
separately. It must be stated that in the median results of cell viability presented in 
Figure 2 (Section A), there are also results of both patients presented in Sections B 
(better responder to CM than FM) and C (resistant to therapy). The median results 
of cell viability for patients B and C could be misleading and suggest that both 
patients should be administered with fludarabine and cyclophosphamide. For both 
patients (see Figure 2B and C) fludarabine will not be an optimal drug for curing.
Figure 1. 
Personalized therapy for CLL patient. Results of cell sensitivity with anticancer agents. Cell viability of 
chronic lymphocytic leukemia cells incubated for 48 h without Co and with anticancer drugs; Co, controlled 
untreated CLL cells; CM, cladribine + mafosfamide; FM, fludarabine + mafosfamide; RtCM (20 or 40 µM), 
rituximab + CM. Differences in thermal profiles were analyzed by differential scanning calorimetry (DSC). Analysis 
of protein expression related to apoptosis (PARP cleavage; 89 kDa) or actin (43 kDa) was studied by Western blot.
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Using above tests we can also monitor the differences in drug sensitivity during 
disease development (Figure 3) [10]. As presented in Figure 3 results of cell sensi-
tivity to anticancer agents could change during disease development. In active form 
of disease (year 2013), a higher leukocytosis than 18 months earlier results (year 
2011) was noticed. For the same patient, we can observe differences in leukemic cell 
sensitivity to the same anticancer agents, i.e., combinations of cladribine + mafos-
famide (cyclophosphamide), CM; fludarabine + mafosfamide (cyclophosphamide), 
FM; rituximab + CM (RCM); kinetin riboside (RK), that confirm the usefulness 
of personalized therapy tests also in monitoring of disease development and the 
changes in drug sensitivity [10].
Results of cell viability of chronic lymphocytic leukemia cells incubated for 48 h 
(24, 48 h) without Ctr and with anticancer drugs; CM, cladribine + mafosfamide; 
FM, fludarabine + mafosfamide; RCM, rituximab + CM; Rit, rituximab; RK, 
kinetin riboside [10].
The existing data confirm that in the development of CLL, some disturbances in 
cell signaling [16], apoptosis inhibition, or changes on epigenetic level [17–20] are 
observed. Moreover, the results of studies confirm that there are several molecules 
generated from encoded sequences of genes, characterized as miRNA that could 
affect gene expression, mainly by silencing. It could also be involved in regulation 
of protein synthesis important for cell cycle.
Figure 2. 
Cell viability of chronic lymphocytic leukemia cells incubated for 48 h without Ctr and with anticancer drugs; 
CM, cladribine + mafosfamide; FM, fludarabine + mafosfamide; A, median value of cell viability; B, results 
obtained for cells of CLL patient (better responded to CM than to FM); C, results obtained for cells of CLL 
patient resistant to treatment.
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The background of chemoresistance includes one or more of the following 
mechanisms: induction of DNA repair, silencing of gene expression, some altera-
tions in metabolism or in drug target structure, modifications in cell membrane or 
microenvironment composition, elevated expression of drug efflux pumps, and 
inhibition of apoptosis [21–24].
Everything is very complex, and on the one hand familiar diversities could affect 
cell signaling and metabolism; on the other hand also environmental factors could 
be important for final reaction of our cells and bodies to drugs, even human diet.
At the moment it is better to analyze the total effect of drug activity on leukemic 
cells before drug administration to CLL patient, preventing resistance to treatment.
Diagnostics for CLL are still based on the analysis of expression of characteristic 
clusters of differentiation (CD) as well as the presence of cytogenetic alterations 
(chromosomal aberrations) [25–27].
The currently used drugs in hematological clinics for CLL treatment are usu-
ally directed toward inhibition of Bcl-2 gene expression (venotoclax), inhibition 
of pathways related with signal transduction, for example, involved in inhibition 
of competitive binding of ATP to Bruton kinase (ibrutinib), or inhibition of PI3K 
signaling (idelalisib) [27–31]. Both kinases are involved in B-cell receptor signaling.
Venotoclax (VEN, ABT-199) is a selective inhibitor of antiapoptotic protein 
Bcl-2 expression. It is a BH3-mimetic molecule targeting BCL-2. VEN binds to 
BCL-2 and could activate BIM and induce apoptosis signaling. VEN demonstrates 
an activity in patients with poor prognostic, 17p-deleted chronic lymphocytic 
leukemia (CLL) [28]. VEN shows clinical activity on many hematological malignan-
cies, lymphomas, acute myeloid leukemia, and early T-cell precursor ALL.
Ibrutinib directly works as an inhibitor of Bruton tyrosine kinase (BTK). 
Interestingly, there is crosstalk between Bruton tyrosine kinase signaling and 
bioenergetic stress responses. In primary chronic lymphocytic leukemia cells, a 
pharmacological interference between mitochondrial ATP synthesis and glucose 
metabolism could affect BTK activity. Moreover, ibrutinib could induce bioener-
getic stress responses [32] that might affect for its resistance. Therefore ibrutinib 
activity could be regulated by glucose level, and patients with hyperglycemia might 
Figure 3. 
Differences in drug sensitivity during disease development for the same CLL patient (results from year  
2011 and 2013).
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be resistant to ibrutinib treatment in TP53 deficient chronic lymphocytic leukemia 
(CLL) lymphocytes [28].
Idelalisib is an inhibitor of the delta isoform of the phosphatidylinositol 3-kinase 
(PI3K). Drug could be active on cell proliferation, survival, or even induction of 
apoptosis. Moreover the strong heterogeneity of CLL feature and involvement in 
PI3K signaling could be a reason of differences between patients in clinical develop-
ment of CLL and diversities in response to therapy. Idelalisib could induce several 
possible side effects, including hepatotoxicity, diarrhea, colitis, pneumonitis, or 
intestinal perforation. A special importance for personalize therapy is a chance 
to avoid resistance to treatment and reduce the development of secondary cancer 
(melanoma, head and neck, prostate, breast, or lung) [16].
Drugs usually for some patients lead to disease remission that could last for 
many years. It is also possible that for the group of patients, drugs could be ineffec-
tive and cause resistance to therapy [31]. For CLL, drugs based on higher genera-
tions of monoclonal antibodies could usually cause cytotoxicity in B-cells and fast 
reductions in the number of B lymphocytes from peripheral blood, decreasing 
patient’s immunological strength. To increase drug activity, the combined therapy 
based on few drugs could in theory increase patients’ response to therapy. Based on 
our experience with leukemic cell incubations with anticancer drug(s), sometimes 
it does work this way; for other patients, for example, the addition of second drug 
will not change cell response to anticancer agents (Figure 1). It could prove that 
sometimes one drug will be enough instead of combined therapy that will not be 
more effective, will cause patient’s weakness, and will not improve the final effect 
of treatment. For the group of patients, who do not react at standard way to anti-
cancer drugs or are resistant to treatment, choosing the optimal way of treatment 
for patient seems to be very important for his curing.
There are several molecules, for example, generated from encoded sequences 
of genes (pre-mRNA), characterized as miRNA, that could affect gene expres-
sion, mainly by their silencing, and could decrease or block protein expression. 
Because of a high complexity of metabolic reactions and several metabolic pathways 
included inside the cells that could be activated by drugs, hormonal regulation of 
human body metabolism and several different factors, previously taken medica-
ments or even diet, could affect patient’s response to anticancer treatment [19, 21, 
23, 32, 33]. Several potential targets for anticancer agents met in the human body 
are a reason of drug’s side effect. Moreover, some familiar or personal diversities 
could also change patient reactivity to drugs. Drug reactivity could also be affected 
by environmental factors or even patient’s diet.
At the moment it is better to analyze the total effect of drug activity on leukemic 
cells before drug administration to patient to avoid potential resistance to treatment.
2. Conclusion
The best way to prevent diseases is a prophylactic. The well-balanced healthy 
diet, physical exercises, supplementation of probiotic bacteria, or screening tests 
showing our health condition are the best way to prevent diseases and increase 
life expectancy. We have to start thinking about our health since childhood, and 
several wrong decisions could shorten our life. Because of a high complexity in 
cells and human body function and not enough knowledge related to disease 
etiology, currently it is better to analyze in vitro the apoptosis induction potential 
of leukemic cells incubated for 48 h with anticancer drugs before drug administra-
tion to CLL patient to exclude resistance to treatment. The resistance to treatment 
is usually confirmed in CLL cells incubated for 48 h with anticancer drug(s). 
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While, after 24 h of cell incubation in vitro with anticancer drug(s), the necessity 
of dose modification usually for lower values in the case of CLL patients’ more 
sensitive cells to drug(s) was noticed. It must be underlined that sometimes the 
addition of drug (rituximab) as presented in Figure 1 does not change anything in 
CLL cell reactivity to drugs (CM and Rit20CM).
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